Drug search by name

Remodulin injection and Hepatic impairment

Result of checking the interaction of drug Remodulin injection and disease Hepatic impairment for safety when used together.

Check result:

Remodulin injection <> Hepatic impairment

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

The use of the extended-release tablet formulation of treprostinil is contraindicated in patients with severe hepatic impairment (Child Pugh Class C). There is a marked increase in the systemic exposure to treprostinil in hepatically impaired patients. It is recommended to start patients with mild hepatic impairment (Child Pugh Class A) at 0.125 mg BID with 0.125 mg BID dose increments every 3 to 4 days and to avoid use of treprostinil in patients with moderate hepatic impairment (Child Pugh Class B).

Remodulin injection

Generic Name: treprostinil

Brand Name: Remodulin, Orenitram, Tyvaso, Tyvaso Refill Kit, Tyvaso Starter Kit

Synonyms: Remodulin (injection), Remodulin

What is Remodulin injection?